Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Rating Reaffirmed by Wedbush

Y-mAbs Therapeutics (NASDAQ:YMAB)‘s stock had its “outperform” rating reissued by equities research analysts at Wedbush in a research note issued on Tuesday, RTT News reports. They presently have a $12.00 price target on the stock. Wedbush’s price objective indicates a potential upside of 128.57% from the company’s current price.

YMAB has been the topic of a number of other reports. HC Wainwright restated a “buy” rating and set a $11.00 price target on shares of Y-mAbs Therapeutics in a report on Monday, August 14th. Canaccord Genuity Group increased their price target on Y-mAbs Therapeutics from $21.00 to $22.00 and gave the stock a “buy” rating in a report on Tuesday, July 25th. Morgan Stanley cut their target price on Y-mAbs Therapeutics from $7.00 to $5.00 and set an “underweight” rating on the stock in a report on Monday, August 14th. Finally, JPMorgan Chase & Co. cut their target price on Y-mAbs Therapeutics from $8.00 to $7.00 and set an “underweight” rating on the stock in a report on Tuesday, August 22nd. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $11.71.

Y-mAbs Therapeutics Price Performance

Shares of YMAB stock opened at $5.25 on Tuesday. The business’s 50 day simple moving average is $5.27 and its 200 day simple moving average is $6.44. Y-mAbs Therapeutics has a one year low of $2.70 and a one year high of $10.95. The stock has a market capitalization of $229.01 million, a PE ratio of -11.93 and a beta of 0.66.

Institutional Investors Weigh In On Y-mAbs Therapeutics

Large investors have recently made changes to their positions in the business. Tower Research Capital LLC TRC increased its holdings in Y-mAbs Therapeutics by 924.1% in the 1st quarter. Tower Research Capital LLC TRC now owns 5,899 shares of the company’s stock worth $30,000 after acquiring an additional 5,323 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Y-mAbs Therapeutics by 248.7% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,513 shares of the company’s stock worth $99,000 after acquiring an additional 4,645 shares during the last quarter. BNP Paribas Arbitrage SA increased its holdings in Y-mAbs Therapeutics by 172.5% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 7,980 shares of the company’s stock worth $121,000 after acquiring an additional 5,052 shares during the last quarter. Avestar Capital LLC bought a new position in Y-mAbs Therapeutics in the 2nd quarter worth about $68,000. Finally, Graham Capital Management L.P. bought a new position in Y-mAbs Therapeutics in the 2nd quarter worth about $68,000. 45.45% of the stock is owned by hedge funds and other institutional investors.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma.